.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,039,931

« Back to Dashboard
Patent 6,039,931 protects EOVIST and is included in one NDA.

This patent has thirty-two patent family members in twenty-four countries.

Summary for Patent: 6,039,931

Title: Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
Abstract:Compounds of general Formula I ##STR1## wherein Z.sup.1 and Z.sup.2 in each case independently mean the residue wherein m and n means the numbers 0-20, k, l, q and r means the numbers 0 and 1, and R means a hydrogen atom, an optionally OR.sup.1 -substituted C.sub.1 -C.sub.6 -alkyl residue, or a CH.sub.2 COOR.sup.1 group with R.sup.1 meaning it hydrogen atom, a C.sub.1 -C.sub.6 -alkyl residue, or a benzyl group, X means a hydrogen atom and/or a metal ion equivalent of an element of atomic number 21-29, 42, 44 or 57-83, with the provisos that at least two the substituents X stand for a metal ion equivalent; that one of the substituents Z.sup.1 and Z.sup.2 stands for a hydrogen and the other is not H; that--if n and l each mean the number 0--k and r do not simultaneously mean the number 1; that --(O).sub.r --R is not --OH; and that Z.sup.1 and Z.sup.2 are not --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOCH.sub.2 C.sub.6 H.sub.5 or --CH.sub.2 --C.sub.6 H.sub.4 --O--(CH.sub.2).sub.5 --COOCH.sub.2 C.sub.6 H.sub.5, as well as their salts with inorganic and/or organic bases, amino acids or amino acid amides, are valuable pharmaceutical agents, e.g., for NMR.
Inventor(s): Schmitt-Willich; Heribert (Berlin, DE), Platzek; Johannes (Berlin, DE), Gries; Heinz (Berlin, DE), Schumann-Giampieri; Gabrielle (Berlin, DE), Weinmann; Hanns-Joachim (Berlin, DE), Vogler; Hubert (Berlin, DE), Deutsch; Julius (Berlin, DE), Conrad; Juergen (Berlin, DE)
Assignee: Schering Aktiengesellschaft (Berlin, DE)
Application Number:08/319,357
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
EOVIST
gadoxetate disodium
SOLUTION;INTRAVENOUS022090-001Jul 3, 2008RXYes6,039,931► subscribe MAGNETIC RESONANCE IMAGING OF THE LIVER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,039,931

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany39 22 005Jun 30, 1989

Non-Orange Book Patents for Patent: 6,039,931

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,798,092 Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production► subscribe
5,695,739 Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,039,931

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria115546► subscribe
Australia5802490► subscribe
Australia637111► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc